Common stock, par value $0.001 per share
- Symbol
- LFCR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01, 9.01 · 8-K
LIFECORE BIOMEDICAL, INC. \DE\
LFCRNASDAQEQUITYCurrent
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Lifecore Biomedical, LLC (“Lifecore”), a subsidiary of Lifecore Biomedical, Inc. (the “Company”), entered into an Amendment No. 3 to Amended and Restated Contract Manufacturing Agreement (the “Third Amendment”) with Alcon Research, LLC (“Alcon”) that is effective November 1, 2026.…
Company context
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com. The contents of Lifecore’s website are not incorporated by reference into this press release.
Current securities
Registered securities in this filing
LIFECORE BIOMEDICAL, INC. · 8-K · Filed 2026-09-29
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On September 24, 2026, Lifecore Biomedical, LLC (“Lifecore”), a subsidiary of Lifecore Biomedical, Inc. (the “Company”), entered into an Amendment No. 3 to Amended and Restated Contract Manufacturing Agreement (the “Third Amendment”) with Alcon Research, LLC (“Alcon”) that is effective November 1, 2026. The Third Amendment amends that certain Amended and Restated Contract Manufacturing Agreement between Alcon and Lifecore effective as of December 31, 2023, as amended by an Amendment No. 1 dated as of May 2, 2024 and an Amendment No. 2 dated as of June 13, 2025 (as amended, the “Contract Manufacturing Agreement”).
Pursuant to the Third Amendment, the parties agreed to extend the term of the Contract Manufacturing Agreement from December 31, 2031 to an Initial Term ending December 31, 2034. Thereafter, the Initial Term will automatically renew for successive 24-month periods, unless either party provides proper notice. The parties also amended an exhibit to the Contract Manufacturing Agreement to establish Alcon’s minimum purchase obligations through 2034, and certain supply obligations of Lifecore. Pursuant to the Third Amendment, Lifecore also agreed that, commencing on November 1, 2026, it would not enter into new agreements to develop, supply or manufacture certain types of products that directly compete with certain Alcon products. This restriction does not limit Lifecore from performing its obligations under its agreements in existence prior to such date or from renewing, extending, amending or replacing these pre-existing agreements on substantially similar terms or terms more favorable to Lifecore.
The foregoing description of the Third Amendment does not purport to be complete and is subject to, and qualified in its entirety by, reference to the text of the Third Amendment, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.